Gilead Sciences Inc. , the world’s third-biggest biotechnology company, said on Monday it agreed to acquire Myogen Inc. for $2.5 billion in a surprise transaction that gives Gilead access to Myogen’s experimental hypertension drugs.
*For more on this story,
read the full Reuters
article.
